Business Context and Reporting Period
Company: Humacyte, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2026
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
- Regulatory Status Change: The Company previously received notice on May 4, 2026, of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to a closing bid price below $1.00 per share for 30 consecutive business days ended May 1, 2026.
- Compliance Regained: On June 5, 2026, the Company received notification from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement.
- Resolution: Nasdaq has officially considered the matter closed.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the resolution of the listing deficiency without providing forward-looking financial guidance or operational outlook.
Risks and Contingencies: The primary risk addressed was the potential delisting from The Nasdaq Global Select Market due to low stock price. This risk has been mitigated as of the report date. No other unusual items or contingencies are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of HUMA on The Nasdaq Stock Market to ensure continued compliance with the $1.00 minimum bid price.
- Review the Company's recent 10-Q or 10-K filings for financial performance data, as this 8-K contains no financial metrics.
- Monitor future Nasdaq communications to ensure no new compliance notices are issued.